Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Expenses for 4 consecutive years, with $55.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 34.48% to $55.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $312.5 million, a 3.77% decrease, with the full-year FY2025 number at $312.5 million, down 3.77% from a year prior.
  • Operating Expenses was $55.9 million for Q4 2025 at Phathom Pharmaceuticals, down from $58.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $103.7 million in Q1 2025 to a low of $30.1 million in Q1 2023.
  • A 4-year average of $61.1 million and a median of $57.2 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 162.6% in 2024, then plummeted 34.48% in 2025.
  • Phathom Pharmaceuticals' Operating Expenses stood at $46.6 million in 2022, then surged by 50.92% to $70.4 million in 2023, then increased by 21.13% to $85.3 million in 2024, then crashed by 34.48% to $55.9 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Operating Expenses are $55.9 million (Q4 2025), $58.6 million (Q3 2025), and $94.4 million (Q2 2025).